Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Business
  • Published:

Copycats gear up to dog biotech brands

Nature volume 443, pages 496–497 (2006)Cite this article

Pressure is mounting on US regulators to create an approval track for generic versions of biotechnology drugs. Meredith Wadman reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Meredith Wadman
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

In brief

News In Brief

In brief

Path to approval proves rocky for copycat biodrugs

Related external links

Biotechnology Industry Organization

Generic Pharmaceutical Association

Barr Pharmaceuticals

Engel & Novitt law firm

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wadman, M. Copycats gear up to dog biotech brands. Nature 443, 496–497 (2006). https://doi.org/10.1038/443496a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/443496a

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing